Patent ID: 6399608
Filing Date: 2002-06-04
Classification: A61K,A61P

Abstract:
A pharmaceutical product comprising an SSRI and a non-sedating anxiolytic compound which is a modulator of the benzodiazepine binding site of the human GABAA receptor, having a binding affinity (Ki) for the &agr;3 subunit of the human GABAA receptor of 10 nM or less, which elicits at least a 40% potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the &agr;3 subunit of the human GABAA receptor, and which elicits at most a 30% potentiation of the GABA EC20 response in stably transfected cell lines expressing the &agr;1 subunit of the human GABAA receptor for simultaneous, separate or sequential administration.